Understand the source comparison
Best Peptides for Erectile Dysfunction: Evidence-Based Comparison
Before reviewing individual peptides, understand that clinical response correlates with dysfunction subtype. No single peptide works universally. The table below ranks peptides by published efficacy, mechanism, tolerability, and practical feasibility. PT-141 (
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before reviewing individual peptides, understand that clinical response correlates with dysfunction subtype. No single peptide works universally. The table below ranks peptides by published efficacy, mechanism, tolerability, and practical feasibility.
- PT-141 (Bremelanotide)
- MC3R/MC4R agonist. Central arousal via hypothalamic dopamine modulation
- 52% responder rate (IIEF improvement ≥1 grade) in Phase 3 trials
- Nausea (40%), flushing (13%), headache (11%). Generally mild and transient
- Subcutaneous injection, 1.75mg on-demand
- High. FDA-approved, commercially available, predictable onset
- Kisspeptin-10
- GPR54 agonist. Stimulates GnRH release, increases endogenous testosterone
- 36% improvement in erectile response to sexual stimuli; +42% testosterone increase in responders
- Minimal. Transient warmth at injection site, no significant systemic effects reported
- IV infusion (1.0nmol/kg) or subcutaneous (500–1000mcg)
- Low. Requires clinical infusion or high-dose subcutaneous, no approved formulation
- Melanotan II
- Pan-melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R). Central + peripheral effects
- 65–70% improvement in erectile rigidity in early trials (small sample sizes)
- Nausea (60%), facial flushing (45%), spontaneous erections (15%), darkening of skin/moles
- Subcutaneous injection, 0.5–1.5mg on-demand or cyclically
- Moderate. Widely available through research suppliers, but tolerability limits consistent use
- Bottom Line: PT-141 offers the best balance of efficacy, safety, and practical use for men with psychogenic or desire-related erectile dysfunction. Kisspeptin-10 is the most targeted option for secondary hypogonadism but requires clinical administration. Melanotan II delivers the highest raw response rate but adverse events make it unsuitable for most men seeking reliable on-demand use.